Latest news and press releases about Savara Inc. (SVRA): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
Price
| Price | $5.13 |
| Market Cap | $1.1B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 9.09 |
| EV / EBITDA | -7.83 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -90.28% |
| Return on Invested Capital | -82.30% |
| Return on Assets | -72.50% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: BCAX · EYPT · GERN · GHRS · KURA · NBTX · PROK
Explore sector: Healthcare · Biotechnology
More sections of SVRA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks